Anti-obesity drugs: Fighting fat

@article{Kirkpatrick2006AntiobesityDF,
  title={Anti-obesity drugs: Fighting fat},
  author={Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  year={2006},
  volume={5},
  pages={634-634}
}
  • P. Kirkpatrick
  • Published 1 August 2006
  • Biology
  • Nature Reviews Drug Discovery
Rising levels of obesity and associated health problems in many countries worldwide have led to a burgeoning interest in drugs that could promote weight loss. Writing in the British Journal of Pharmacology, Pauwels and colleagues now provide evidence that a novel 5-hydroxytryptamine (5-HT)6 receptor partial agonist — known as E-6837 — could represent a novel approach for the management of obesity. Several previous investigations have indicated that the 5-HT6 receptor, which is distributed… 

References

SHOWING 1-2 OF 2 REFERENCES

Chronic 5‐HT6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats

Results show that the 5‐HT6 receptor partial agonist, E‐6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine.

Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.

Novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT(6) receptor ligands, which should allow for the detailed study of the role of the 5- HT( 6) receptor in relevant animal models of disorders such as cognition deficits, depression, anxiety, or obesity.